<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369836</url>
  </required_header>
  <id_info>
    <org_study_id>B3461009</org_study_id>
    <nct_id>NCT01369836</nct_id>
  </id_info>
  <brief_title>Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects</brief_title>
  <official_title>An Investigator And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06291826 (Tafamidis) After Single Oral Administration To Japanese And Western Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the following:

        -  To evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered
           tafamidis in Japanese and Western healthy volunteers at single dose.

        -  To compare Japanese and Western PK profiles.

        -  Determine the PD stabilization effect of tafamidis on human transthyretin (TTR) in a
           validated ex vivo assay.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of tafamidis over time (AUClast).</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of tafamidis over time (Cmax).</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of tafamidis over time (Tmax).</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>If data permit, AUCinf and t1/2 will be determined.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent stabilization of TTR tetramer will be defined at Cmax in each subject and compared between Japanese volunteers and Western volunteers.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>20 mg soft gelatin capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg (20 mg*2) soft gelatin capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis meglumin</intervention_name>
    <description>A single oral dose of 20 mg capsule</description>
    <arm_group_label>20 mg soft gelatin capsule</arm_group_label>
    <other_name>PF-06291826</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis meglumin</intervention_name>
    <description>A single oral dose of 40 mg capsule.</description>
    <arm_group_label>40 mg (20 mg*2) soft gelatin capsule</arm_group_label>
    <other_name>PF-06291826</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single oral dose of matched placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Not Specified</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or females.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Females of childbearing potential who are unwilling or unable to use an acceptable
             method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461009&amp;StudyName=Study%20Of%20Single%20Doses%20Of%20PF-06291826%20%28Tafamidis%29%20In%20Japanese%20And%20Western%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>September 12, 2011</last_update_submitted>
  <last_update_submitted_qc>September 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tafamidis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>TTR stabilization</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

